**Oral abstracts of the HIV Cure and Reservoir Symposium 2017**

**O1**

Towards a block-and-lock strategy: LEDGINs hamper the establishment of a reactivation competent reservoir

Gerlinde Vansant, Lenard S Vranckx, Irena Zurnic, Suha Saleh, Anne Bruggemans, Frapke Christ, Zeger Debayer

Laboratory of Molecular Virology and Gene Therapy, Department of Pharmacological and Pharmaceutical Sciences, KU Leuven, Belgium.

**Background:** Persistence of latent provirus is the main barrier towards a cure for HIV. We propose a novel strategy to reduce the HIV reservoir by drug-induced retargeting of HIV integration. A novel class of integration inhibitors, LEDGINs, inhibits the interaction between HIV integrase (IN) and the LEDGF/p75 cofactor, the main determinant of integration site selection. This results in an allosteric inhibition of HIV IN (early effect). Moreover, when present during production, progeny virus displays morphological and replication irregularities (late effect).

**Methods:** Integration sites were sequenced using 454 pyrosequencing. To evaluate reactivation potential, cell lines were infected with a double-reporter virus and LEDGIN was added during infection (early effect) or during production of the virus (late effect). Cells were reactivated and analyzed by FACS. In a multiple round experiment, primary activated CD4+ T cells were infected with wild type NL4-3 virus in the presence of LEDGIN or RAL. Cells were reactivated and virus production was measured by p24 ELISA.

**Results and conclusions:** LEDGIN-mediated inhibition of the LEDGF/p75-IN interaction blocks replication and relocates integration out of transcription units. This retargeting resulted in a residual reservoir that contains up to 95% of latent cells that are resistant to reactivation. In activated CD4+ T-cells, both LEDGIN and RAL reduced infection. The residual provirus established under LEDGIN treatment was hampered for reactivation, a phenotype not observed with RAL. Addition of LEDGINs early during acute infection does affect the formation of the latent reservoir. Bringing the majority of residual proviruses in a state of deep latency and defective for reactivation might represent an attractive approach to achieve an HIV remission.

**O2**

Identification of a new factor involved in DNA methylation-mediated repression of latent HIV-1

S Bouchat1*, R Verdikt1*, N Delacourt1, C Vanhulle1, B Van Driessche1, G Darcis1,2, A Pasternak2, V Avettrandt-Fenoel4, C Necsoi5, V Ledouce6, M Bendounou1, C Schwartz1, S De Wit7, A Saez-Cirion8, V Berkhout3, V Gautier6, C Schwartz7, C Van Lint1

1Service of Molecular Virology, ULB, Brussels, Belgium, 2Service des Maladies Infectieuses, Université de Liège, Belgium, 3Laboratory of Experimental Virology, Academisch Medisch Centrum, Amsterdam, Netherlands, 4Service de Virologie, Necker, France, 5Service of Infectious Diseases, Université Libre De Bruxelles, Belgium, 6UCD-CRiD, Dublin, Ireland, 7Institut de Parasitologie et de Pathologie Tropicale, Unistra, France, 8HIV Inflammation and Persistence Unit, Institut Pasteur, France, 9Institut Universitaire de Technologie Louis Pasteur de Schilfgheim, Unistra, France

*Contributed equally

The DNA methylation profile of the HIV-1 latent 5’LTR is heterogeneous. Previously, we reported that the DNA methylation inhibitor decitabine induces different levels of HIV-1 reactivation in vitro and ex vivo. However, the mechanism of DNA methylation-mediated HIV-1 silencing remains unclear. To explore this mechanism, we took advantage of two latently-infected cell lines representing distinct integration sites, and showed that these two cell lines exhibited similar levels of 5’LTR CpG methylation in basal condition but different DNA methylation extents in response to decitabine. Methylation at CpG dinucleotides following decitabine-induced HIV-1 reactivation occurred at specific and reproducible CpG positions that differed depending on the two cell lines studied. Interestingly, a site comprising one of this hotspot for decitabine-induced demethylation was shown to bind UHRF1, only in one of cell line. Treatment with decitabine caused a decreased in vivo UHRF1 recruitment to the 5’LTR. UHRF1 knockdown using RNA interference and pharmacological approach showed increased levels of HIV-1 production in latently-infected cells and of HIV-1 transcription in ex vivo cell cultures from cART-treated aviremic HIV+ patients, respectively. UHRF1 has not previously been identified as a regulator of HIV latency and might thus constitute a new therapeutic target for HIV cure strategies.

**O3**

Heme-arginate as a latency-reversing agent for HIV-1 cure

Michaela Madlenakova1,2, Prakash Shankaran1, Vera Hajkova1,2, David Jilich3, Ladislav Machala1, Pavel Martasek1, Zora Melkova1,2

1Department of Immunology and Microbiology, Charles University, 2nd Faculty of Medicine, Prague, Czech Republic, 3BIOCEV, Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University, Vestec, Czech Republic, 4AIDS Center, Na Bulove Hospital, Prague, Czech Republic

Current antiretroviral therapy does not lead to virus elimination in HIV-1-infected patients as HIV-1 can establish a highly stable reservoir of latently infected cells. Approaches towards HIV-1 cure involve namely attempts to reactivate and purge HIV-1 latently infected cells. Since the current strategies for latent HIV-1 reactivation do not seem to affect the size of the latent pool, it is important to search for new latency reversing agents and their combinations. Our laboratory has demonstrated that Normosang (HA, Orphan Europe), a human hemin containing compound used to treat acute porphyria, could strongly potentiate reactivation of latent HIV-1 induced by PKC inducers in cell lines, while it inhibited HIV-1 replication in acute infection through its effect on reverse transcription. The stimulatory effects of Normosang involve a heme/iron-mediated Fenton reaction resulting in the increased redox stress (Shankaran et al., 2011; Shankaran et al., 2017).

To confirm our original hypothesis that Normosang could be used as a latency reversing agent in human, we plan to perform a study characterizing the in vivo effects of Normosang on reactivation of the latent HIV-1 in HIV-infected patients on combined antiretroviral therapy (cART) including an integrase inhibitor. At specific time-points after the intravenous administration of Normosang, we will quantify cell-associated HIV-1 RNA in PBMCs of HIV+ patients using 2-step semi-nested RT-qPCR. Simultaneously, levels of parameters characterizing heme and iron metabolism will be determined. Our work defines a new redox-based approach to the HIV-1 latency reversal and provides basis for new therapeutic strategies that might lead to HIV-1 cure.

**O4**

Early start of antiretroviral therapy (ART) during primary HIV infection (PHI) is associated with faster optimal immunological recovery: results of Italian Network of ACuTe HIV InfectiON (INACTION) retrospective study

A Muscatello1, A Bandera1, M Fabbiani1, I De Benedetto1, A Ammassari2, A Antinori2, A Calagna2, BM Celesia2, A Cingolani3, G d’Ettorre2, A Di Biagio2, E Foca3, E Girardì2, R Gulminetti2, G Madeddu2,3, G Marchetti1,2, C Mussini1,2, S Nozza1,2, G Orofino2,4, D Ripamonti1,2, S Rusconi1,2, G Tambussi1,2, A Gori1 on behalf of INACTION study group

© 2017 The Authors. Journal of Virus Eradication published by Mediscript Ltd. This is an open access article published under the terms of a Creative Commons License.
The expression profile of host restriction factors in different cohorts of HIV-1-infected patients

C Van Hecke1, E Malatinikova1, W De Spiegeleere2, M Sips1, K Vervisch1, C Verhofstede1, M Johnson4, S Kinloch-de Loës4, Daria J Hazuda1, Martin Robbecrechts1, Andreas Hüser2, Daria J Hazuda1, Jay A Grobler1, Aubrey Stoch1, Marian Iwamoto1

1HIV Cure Research Center, UGent, Belgium, 2Department of Morphology, UGent, Belgium, 3AIDS Reference Laboratory, UGent, Belgium, 4Royal Free Hospital, London, UK

*Contributed equally

After HIV-1 infection, several antiviral host genes are upregulated to suppress viral infectivity. These antiviral factors, defined as restriction factors, are part of a first line innate antiviral immune response. In this study, host restriction factor expression (APOBEC3G, SAMHD1, tetherin, TRIM5α, MX2, SLFN11 and PAF1) was determined in different cohorts of HIV-1 infected patients.

The expression profile of seven HIV-1 restriction factors was evaluated in 104 HIV-1 infected patients from six pre-defined cohorts: long-term-treated patients where ART is initiated during seroconversion (Early treated; N=24) or chronic infection (Late treated; N=32), long term non-progressors (LTNPs; N=17), recent ART-naïve seroconverters (Recent SRCV; N=19) and ART-naïve chronically infected patients (Chronic naïve; N=12). Patients were recruited in two clinical centers (Royal Free Hospital London and Ghent University Hospital) and an additional group of healthy individuals (N=14) was included as a control.

In general, elevated restriction factor levels for Recent SRCV, LTNPs, early treated patients and chronically infected therapy naïve patients were determined. The restriction factor levels of healthy individuals and late treated patients remain low at similar levels. For example, APOBEC3G was significantly upregulated in ART-naïve recent SRCV and long-term-treated patients that started therapy early (Early treated), in comparison to healthy individuals (p < 0.001; p < 0.001). APOBEC3G was also elevated in comparison to long-term-treated patients started on ART during chronic HIV-1 infection (Late treated) (p < 0.01, p < 0.001). APOBEC3G levels were positively correlated with CD4 count at borderline significance level (r=0.44, p=0.076). Host restriction factor expression levels are elevated in recent seroconverters as an early antiviral host defense mechanism. LTNPs are able to maintain slightly upregulated restriction factor levels, suggesting a mechanism contributing to their non progressing phenotype. For HIV-1 patients on treatment, restriction factor levels are upregulated in the early treated in comparison to the late treated HIV-1 patients. HIV-1 patients that started treatment early are able to maintain higher restriction factor levels which could contribute to a better disease control.
Does viral suppressive capacity in cART-treated HIV-infected patients correlate with disease parameters, viral reservoir measures or cytotoxic T cell phenotype?

P Pannus1, P Adams2, E Willems1, L Heyndrickx1, M Van Frankenhuysen1, E Florence1, M Kiselnova4, S Rutsaert5, K Vervisch5, W Despiegelaere5, C Devaux2, L Vandekeerckhove2, G Vanham1

1Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium, 2Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg, 3AIDS Reference Clinic, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium, 4HIV Cure Research Center (HCRC), Ghent University, Ghent, Belgium

**Background:** A combination of potent HIV-specific immune responses and a small latent viral reservoir is likely required to achieve post-treatment control of HIV infection. Here we investigated correlations between viral suppressive capacity, phenotype of CD8+ T-cells, clinical parameters and the HIV reservoir.

**Methods:** Thirty-six patients on cART with suppressed viremia and six healthy donors were recruited. Total HIV-1 DNA and unspliced mRNA (usRNA) levels were measured in PBMCs. Viral suppressive capacity of CD8+ T cells and their phenotype (cytokine production, cytotoxicity and immune checkpoint markers) were determined before and after peptide stimulation. In a sub-group of 21 patients infected with HIV subtype B, viral transcriptional activity was quantified with the TILDA assay. Linear regression and student t-test were used for correlation analyses.

**Results:** Total HIV DNA and usRNA levels (median: 187 and 2.2 cps/million PBMCs respectively) were as expected and correlated with each other (p < 0.05). TILDA values ranged from 0 to 313 cells (IQR: 1.4–55.8) with detectable HIV RNA transcripts per million CD4+ T cells after stimulation. CD8+ T-cell suppressive capacity was significantly (p < 0.01) increased with peptide stimulation.

HIV peptide stimulation increased IFN-γ and CD107a expression in CD8+ T cells (p < 0.0065). Viral suppressive capacity correlated with HLA-DR expression in CD8+ T cells during co-culture (p < 0.005). CD8+ T cells of VIA responders had an increased IFN-γ expression between 18 and 42 hours of the CD4/CD8 co-culture. At baseline the suppressive capacity correlated with CD160/PD-1 co-expression in CD8 TEMRA (p < 0.001).

**Conclusions:** In this group of virally suppressed patients, heterogeneity in terms of immune responses and reservoir size was observed, as expected. Interestingly, T-cell exhaustion markers CD160 and PD-1 were predictive of the suppressive capacity of CD8+ T cells.

Integrated site detection in 10 chronically infected patients

Basiel Cole1, Maja Kiselnova1, Sherry McLaughlin1, Sheila Styrchak2, Ward De Spiegaere1, Maria Jose Buzon3, Mathias Lichterfeld4, Lisa Fresken1, Linos Vandenkerckhove1

1HIV Cure Research Center (HCRC), Department of Internal Medicine, Ghent University and Ghent University Hospital, Belgium, 2Seattle Children’s Research Institute, Seattle, USA, 3Department of Morphology, Faculty of Veterinary Medicine, Ghent University, Belgium, 4Vall d’Hebron Institute of Research in Barcelona, Spain, 5Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA, 6Infectious Disease Division, Massachusetts General Hospital, Boston, USA

*Contributed equally

HIV-1 infection remains incurable due to a reservoir of latently infected cells that persists despite sustained antiretroviral treatment. Recently, clonal expansion of latently infected cells has been identified as a driver of reservoir maintenance, representing a new barrier to a cure. Therefore, much effort is being invested in unravelling the dynamics and characteristics of in vivo cell proliferation.

Integration site sequencing with ‘Integration Site Loop Amplification (ISLA)’ was performed to assess clonal expansion in a total of N=10 chronically infected individuals. Previously, reservoir persistence markers such as total HIV-1 DNA, integrated HIV-1 DNA, multiple spliced HIV-1 RNA and unspliced HIV-1 RNA were quantified by droplet digital PCR (ddPCR). In addition, quantitative viral outgrowth assay (qVOA) and tat-rev-induced limiting dilution assay (TILDA) were performed to measure the frequency of replication competent proviruses and the frequency of transcriptionally activatable proviruses respectively.

A total of 408 integration sites were identified from the ten subjects. Clonally expanded infected cells were identified in all but one subject, with a mean level of clonality of approximately 40% (39 ± 23%). Remarkably, one subject had a very highly expanded clone, representing over 90% of the viral reservoir. No preferential orientation of integration was observed with respect to the genome (53% reverse, 47% forward). In contrast, with respect to the genes, integration was biased towards the reverse orientation (74% reverse, 26% forward). Gene ontology testing revealed that integration of proviruses is biased towards genes that play a role in histone modification and regulation of transcription (5% level of significance, Bonferroni corrected).

Furthermore, integration in oncogenes took place at a higher frequency than would be expected at random (p=0.0095, Fisher’s exact test). The above findings show that clonal expansion of infected cells takes place in patients under effective cART, and clones have the potential to grow large and comprise a significant portion of the reservoir. Furthermore, preferential integration into genes involved in transcription and into oncogenes might have forced the host cell to start expanding.

Immunovirological outcome of HIV-infected children living in a resource-limited setting of South Africa

J-C Beghin1,2, J Ruelle1, P Goubau3, M Krishna4, L Hall5, D Van der Linden1

1Université catholique de Louvain, AIDS Reference Laboratory, Medical Microbiology Unit, Belgium, 2Pulmonology, Hôpital Universitaire Des Enfants Reine Fabiola, Belgium, 3Medical Microbiology Unit, Cliniques universitaires Saint Luc, Belgium, 4Pediatrics, Edendale Hospital, South Africa, 5Paediatric Infectious Diseases, Cliniques universitaires Saint Luc, Université catholique de Louvain, Belgium

**Introduction:** Currently available combination antiretroviral therapy (cART) have transformed pediatric HIV-1 from a rapidly fatal illness to a chronic disease. However, immunovirological data collected in Africa are scarce. This study describes the long-term outcome of South African children who started cART before one (Early treated cohort : ETC) and after two years (Late treated cohort : LTC) of age in a resource limited setting (RLS) of South Africa.

**Methods:** 55 and 96 children were included in the ETC and the LTC respectively. Children from both cohorts were subdivided into three subgroups according to CD4+ at cART initiation (<15%, 15 to 24% and ≥25%).

**Results:** Children included in the ETC more often achieved normal CD4+ (% (100% vs 89.6% = 0.014) and reached higher mean CD4+ 6 years after treatment initiation. Children with 15 to 24% CD4+ at cART initiation reached higher CD4+ in the ETC. The proportion of children who experienced virological failure (>1000 cp/ml) was comparable in both cohorts. Persistent undetectable viral load (<50 cp/ml) was more frequent in the ETC (p=0.008). Finally, the proportion of children with detectable viral loads (50 to 1000 cp/ml) at least once after initial virological suppression was higher in the LTC (p=0.002).

**Conclusion:** cART was highly effective both in ETC and LTC. The results of this study demonstrate that early treated children more often achieved normal CD4+, had higher mean CD4+ and more often sustained virological suppression. These results encourage the current recommendations to initiate cART as soon as possible in RLS.
**P1**

**Contribution of IncRNAs in the establishment of HIV latency in central memory CD4 T Cells**

Wim Trypsteen1, Cory White2, Alberto Bosque3, Steve Lefever4, Pieter Mestdagh5, Linos Vandekerckhove1, Christopher Woelk2

1HIV Cure Research Center, Ghent University, Belgium, 2Clinical and Experimental Sciences, University of Southampton, UK, 3Immunobiology, Immunology and Tropical Medicine, George Washington University, USA, 4Center Medical Genetics, Ghent University, Belgium

*Contributed equally

HIV cure research has been hampered by the existence of a latent viral reservoir that persists in infected individuals receiving antiretroviral therapy. To date, most of the cure research has focused on protein coding genes but recently the interest in the study of non-coding RNA has risen, as these molecules could provide insight in new therapeutic strategies.

Transcriptome profiling was performed (total RNA-Seq) in a primary HIV latency model of central memory CD4 T-cells (Tcm) to investigate changes in IncRNA expression. Subsequently, differentially expressed mRNAs and IncRNAs were identified and a guilt-by-association analysis was implemented to infer biological roles for the IncRNAs in HIV latency.

In the primary HIV latency model, we identified 826 mRNAs (87.8%) and 115 IncRNAs (12.2%) that were significantly differentially expressed (FDR<0.05) between uninfected and latently infected Tcm cells. Many of these IncRNAs were associated with pathways involved in cell cycle regulation and pathways with a link to HIV latency: IL-7, PTEN, CSK and CCR5. In addition, a cluster of 17 IncRNAs was associated with the p53 pathway and corroborate earlier findings in this Tcm model that illustrated p53-dependent latency establishment.

One of these upregulated p53-linked IncRNAs, 7SLRNA, has a characterized inhibitory role in the p53 pathway and would suit as a possible new therapeutic target.

Altogether, this study demonstrates that several IncRNAs play a role in HIV latency and can be linked to biological pathways with importance in HIV latency establishment and maintenance. Some of these IncRNAs, i.e. 7SLRNA, represent possible targets for reversing HIV latency and contribute to a HIV cure.

**Conclusion**

To our knowledge, this is the first clinical evaluation in Belgium employing the Sentosaa SQ HIV Genotyping Assay. The NGS appears as a promising tool for the detection of DRM in HIV-1. Results give a higher sensitivity compared to Sanger method. Studies assessing the clinical relevance of DRM in low frequency are needed.

---

**P2**

**Clinical evaluation of the next-generation sequencing (NGS) for detection of drug-resistance mutations in HIV-1**

G Dessilly, L Goeminne, A Duquenne, AT Vandenbroucke, E André, FE Dufrasne, A Martin, B Kabamba, J Ruelle

Université catholique de Louvain, AIDS Reference Laboratory, Institute of Experimental and Clinical Research (IREC), Medical Microbiology Unit (MBLG), Brussels, Belgium

**Introduction:** WHO urges action against HIV drug resistance threat. It is well known that the sensitivity of NGS is vastly superior to Sanger sequencing. The objective of this study was to evaluate the novel NGS HIV-1 drug resistance monitoring system, particularly those in low proportion.

**Materials and methods:** NGS analyses were performed on plasma samples from 41 HIV-1-infected patients with the Sentosaa SQ HIV Genotyping Assay from Vela Dx. This kit was used on a semi-automated Ion Torrent-based platform. Sequences were compared to those obtained by Sanger method. Two samples were added inside and in separated runs. Quality control (QC) were added to control protease (PRO) and reverse transcriptase (RT) sequencing and one to control integrase (INT) sequencing.

**Results:** In the 41 patients analyzed, both methods detected 245 Drug Resistance Mutations (DRMs). The Sentosaa SQ HIV Genotyping Assay detected 38 additional DRMs (mutation frequency ~7%). Sanger method detected 2 additional DRMs, 39A which is not included in the list of mutations by Vela DX because of few clinical impact and the secondary mutation 63Q. The sequences were 98.2% homologous (counting variants as mismatch) and 99.9% homologous (not counting missed variants). Duplicate in a run were 95.7%(99.9%) homologous. Duplicate in two different runs were 98%(100%) homologous. QC results were manually assessed to a score of 340/340 for detection of DRM in PRO and RT and to 100% for INT sequencing.

**Conclusions:** To our knowledge, this is the first clinical evaluation of the next-generation sequencing (NGS) for detection of drug-resistance mutations in HIV-1.

---

**P3**

**An insertion of seven amino acids in the envelope cytoplasmic tail of human immunodeficiency virus type 2 (HIV-2) selected during disease progression enhances viral replication**

François E Dufrasne, Mara Luchetti, Anandi Martin, Jean Ruelle, Patrick Goubau

Université catholique de Louvain, AIDS Reference Laboratory, Medical Microbiology Unit, Brussels, Belgium

**Introduction:** The cytoplasmic tail (CT) of the transmembrane envelope glycoprotein (gpTM) of HIV-2 includes amino acids (aa) sequences similar to lentiviral lytic peptides (LLP) described in other lentiviruses [1,2]. Within the putative LLP-2 region, we previously observed insertions of 3 or 7 aa in sequences deduced from plasma viral RNA of symptomatic HIV-2 infected individuals [3]. Based on these observations, we reproduced the insertions in a molecular clone to assess their impact on replicative fitness and cell death in vitro.

**Methods:** Using a molecular clone of the HIV-2 ROD reference strain, site-directed mutagenesis experiments allowed the generation of plasmids with the insertion L791TAI or L791QRAL TAI in Env protein. After transfection in HEK293T cells, the viral particles were used to infect H9 or Jurkat T cells. Viral release was quantified by RT-qPCR at three and six days post-infection. Cell viability was assessed with the percentage of living cells using a CASY cell counter. The viral infectivity was monitored using the Sentosaa SQ HIV Genotyping Assay.

**Results:** Compared to the control wild-type HIV-2 ROD virus (HIV-2 WT), the clone with a 7 aa insertion enhanced viral release thirteen times. Cell viability was 20% more impaired compared to the wild-type virus. The effect of the 3 aa insertion was milder, with a non-significant trend to enhance viral replication and cell death compared to the wild-type.

Interestingly, the insertions in the Env proteins did not induce a significant increase of viral infectivity, as revealed by the infectivity assay using the TZM-bl reporter cells.

**Conclusion:** A 7 aa insertion including positively charged aa in the putative LLP-2 enhances viral replication and cell death in vitro. The insertions in the Env CT observed in vivo from disease progressors may therefore be involved in the higher viral load observed in these individuals. This study may open the way to the development of laboratory diagnostic tools related to disease progression.

**References**

1. Santos da Silva E, Mulinge M, Perez Bercoff D. The frantic play of the concealed HIV envelope cytoplasmic tail. Retrovirology 2013, 10: 54.
2. Postler TS, Desrosiers RC. The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. J Virol 2013, 87: 2–15.
3. Bakouche N, Vandenbroucke AT, Goubau P, Ruelle J. Study of the HIV-2 Env cytoplasmic tail variability and its impact on Tat, Rev and Nef. PLoS One 2013; 8: e79129.
Long-term aviremia after discontinuation of antiretroviral treatment
Sabine Kinloch-de Loes
Royal Free Hospital, London, UK

Background: Early ART initiation is associated with impact on HIV-1 reservoir establishment and decay with the potential for virological control post-treatment discontinuation. Underlying mechanisms of post-virological control remain unclear. We report on a clade C-infected female patient who has maintained undetectable viremia (VL) for 13 years after stopping a 6-year treatment period initiated at PHI with initial virological failure while on ART and describe her virological parameters and HIV-1 specific T cell responses.

Case report: A 23-year-old female seroconverted with a 3-week-long severe acute retroviral syndrome in October 1997. Blood parameters show a CD4 <200 cells/mm³ on 3 occasions and VL >750,000 HIV-1 copies/mL (clade C) before ART initiation on 20.10.97 (AZT-3TC-indinavir 800 mg tds switched to ritonavir 600 mg bd 2 weeks later). Failure of this regimen over several weeks up to 94,000 c/mL prompted treatment intensification (double-boosted protease inhibitors). Aviremia was achieved in April 1999 on ART which was maintained until January 2004. Following treatment discontinuation aviremia persisted without viral blips for 13 years with preservation of CD4 T cells and CD4/CD8 ratio>1. HLA genotype was not one generally associated with a favourable outcome.

At 10 years of aviremia (2014), total HIV-1 DNA, integrated HIV-1 DNA and 2-LTR circles were 148.93 (95% CI: 76.99–229.64), 134.31 (95% CI: 56.47–304.39) and 3.89 (95% CI: 0–9.15) HIV-1 copies/million PBMCs, respectively. CD4 and CD8 HIV-1 specific T cell responses showed moderately potent CD8® T cell inhibition of a clade-matched HIV-1 isolate equivalent to that which we have observed in ART-naïve chronically infected subjects with VL set-point <10,000 HIV-1 copies/mL. Unusually broad gag-specific IFN-gamma CD4 responses were detected, targeting multiple regions of genetic vulnerability that are associated with virological control. Analysis of CSF (September 2015) showed an undetectable viral load. Her CD4 count in July 2017 was at 942 cells/mm³ with a ratio at 0.99

Conclusion: This is an unusual case of very prolonged aviremia after initial failure of treatment at the time of PHI. Intermediate levels of total and integrated HIV-1 DNA and broad HIV-1 gag-specific CD4 T cell responses, together with preserved CD8® T cell viral inhibitory activity were noted during follow-up. Further insight should be gained into the potential role of CD4 T cells underlying virological control post-ART.